Metraipolis › archive › dc_70692c0ebb40
Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A… — Europe PMC PMID:42317925
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42317925
- DOI
- 10.7759/cureus.109089
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T05:17:26.681Z
- SHA-256 of the archived text
90405f395712e00b99542a5096c3d4b3027e51ecc04bb752ed1ab72cdf233c26- Stable URL of this page
https://metraipolis.com/documento/dc_70692c0ebb40
How to cite
Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A… — Europe PMC PMID:42317925 — Europe PMC (en), https://europepmc.org/article/MED/42317925 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_70692c0ebb40 (Metraipolis archive dc_70692c0ebb40, sha256 90405f395712e00b99542a5096c3d4b3027e51ecc04bb752ed1ab72cdf233c26)
BibTeX
@misc{dc70692c0ebb40,
title = {Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A… — Europe PMC PMID:42317925},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42317925},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_70692c0ebb40; sha256 90405f395712e00b99542a5096c3d4b3027e51ecc04bb752ed1ab72cdf233c26},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42317925. Agents can read the archived copy with the MCP tool read_document.